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Microvolt T-Wave Alternans:
Where Do We Go From Here?
The recent meta-analysis by Gehi et al. (1) assessed the value of
microvolt T-wave alternans (MTWA) testing to predict cardiac
arrhythmic events in differing patient populations. Their analyses
provide a summary estimate of the predictive value of MTWA in
patients with ischemic and non-ischemic cardiomyopathy. In their
discussion, the investigators point out that while MTWA has
shown promise in identifying high-risk patients, studies have been
hampered by small sample sizes. Importantly, this has limited the
comparisons of baseline characteristics between individuals with
negative and non-negative MTWA tests in most studies and has
prevented adequate multivariable adjustment for potential con-
founders.
This raises questions as to whether MTWA is simply a
surrogate marker of patients with greater disease burden and
severity. If so, differences in age, left ventricular ejection fraction
(LVEF), clinical comorbidities, and medication treatment between
individuals with negative and non-negative MTWA tests may
explain its predictive power. We believe that in order for MTWA
to gain wider acceptance as a risk stratification tool, three types of
analyses are needed. First, multivariable modeling that adjusts for
demographics, LVEF, clinical comorbidities, medication treatment,
as well as electrophysiologic variables (e.g., Holter monitoring, QRS
duration, electrophysiologic study) should be done to show that
MTWA is an independent predictor of cardiac arrhythmias. Gehi et al.
(1) themselves acknowledge that MTWA does not offer incremental
prognostic utility unless it can be shown to add predictive power
beyond known risk factors for cardiac arrhythmia (such as LVEF in
patients with ischemic cardiomyopathy).
Second, studies of MTWA should provide analyses of
all-cause mortality in addition to arrhythmic mortality. Prior
studies of MTWA that used a primary end point of cardiac
arrhythmic events may be limited as they did not consider
competing risks whereby MTWA may predict arrhythmic, but
not all-cause, mortality.
Finally, even if future studies demonstrate that MTWA offers
incremental prognostic utility in assessing high-risk patients, its
true utility for risk stratification will only be known when the
mortality reduction benefit of implantable cardioverter-defibrillators
(ICDs) is evaluated in patients who test MTWA-negative and
non-negative. This could be accomplished by randomizing patients to
ICD therapy after MTWA testing, but such a clinical trial might
raise ethical concerns given that some high-risk patients may be
denied life-saving therapy. To justify such a clinical trial, additional
cohort analysis using propensity scores for ICD therapy based on
MTWA status may be needed (2).
Gehi et al. (1) are to be commended for their synthesis of a large
pool of clinical data on MTWA. Future studies of MTWA should
focus on its incremental prognostic utility after multivariable
adjustment, but ultimately the true utility of MTWA in risk-
stratifying high-risk patients will remain uncertain unless it can be
shown that the benefit of ICDs differs by MTWA subgroup.
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REPLY
We appreciate the thoughtful comments of Dr. Chan and col-
leagues regarding our meta-analysis of microvolt T-wave alternans
(MTWA) and wish to expand upon several points (1).
As dicussed by Dr. Chan and colleagues and as we pointed out
in our Discussion section, very few studies have demonstrated
whether MTWA is predictive of future arrhythmic events inde-
pendent of other well-established clinical predictors. There is
substantial evidence regarding the prognostic utility of other risk
predictors, including ejection fraction (EF), signal-averaged elec-
trocardiogram (ECG), heart rate variability, electrophysiologic
study, and baroreflex sensitivity. Though MTWA may be the test
currently in vogue, until MTWA is shown to add substantial
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prognostic value independent of other predictive tests, including
EF, its clinical utility will not be clear.
Also, as pointed out by Dr. Chan and colleagues, future studies
of MTWA should consider all cause and cardiac mortality in
addition to arrhythmic events as primary end points. As stated in
our Discussion section, this is a limitation of prior studies and
likely due to their relatively small size, thus resulting in a lack of
hard end points. As highlighted by the recently published Defibrilla-
tor in Acute Myocardial Infarction Trial (DINAMIT) (2), a decrease
in arrhythmic mortality does not necessarily translate to a decrease
in cardiac or overall mortality.
Additionally, it is important to emphasize an issue not raised by
Dr. Chan and colleagues. That is, a strategy must be developed for
proceeding when MTWA testing is non-diagnostic, which occurs
on average in one-third of patients. Although a non-diagnostic test
seems to carry the same prognosis as a positive test in previous
studies, fundamentally it seems illogical to consider a non-
diagnostic test to be relevant to the prediction of arrhythmic
events. For example, events in these patients may have nothing to
do with MTWA but to other factors such as heart failure.
Thus, future clinical studies of MTWA need to be carefully
designed. Given the current guidelines for implantable
cardioverter-defibrillator (ICD) implantation, it would be uneth-
ical to randomize patients with severe left ventricular (LV)
dysfunction to ICD implantation, dependent on the results of
MTWA testing. The most prudent approach may be the devel-
opment of a sudden-death registry. Patients with structural heart
disease, regardless of EF, could be enrolled in a registry after
performing a variety of prognostic tests on them such as EF,
signal-averaged ECG, and heart rate variability in addition to
MTWA. By following these patients prospectively, clinicians
could better understand how to incorporate MTWA as well as
other established predictors into the decision for ICD implanta-
tion. In fact, we have proposed the development of a scoring
system for risk stratification that incorporates all such variables to
guide ICD implantation for primary prophylaxis (3). In addition,
such an approach may help to utilize our health care resources
more efficiently.
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The Big Chill: Adverse Effects of
Public Reporting on Access to Health Care
When asked by a national news organization to review and
comment on the study published in JACC by Moscucci et al. (1),
I had occasion to read the accompanying editorial by Turi (2). Dr.
Turi, wrapping up an otherwise lucid and well-reasoned editorial,
devotes a paragraph highlighting his own heroism in managing
high-risk patients, then makes the following statement: “The
public, even the well-informed public, frequently ignores published
statistics, perhaps best demonstrated by former President Clinton’s
recent cardiac catheterization and coronary artery bypass graft
surgery (CABG). These procedures were performed in the only two
hospitals in New York State that had risk-adjusted death rates
significantly higher than the statewide average.
Risk-adjusted CABG mortality at Columbia Presbyterian has
never, ever been “significantly” higher than the statewide average.
Because we are referring to an average, let us agree not to be surprised
that roughly one-half the hospitals in New York State have risk-
adjusted CABG mortality that is “higher than the statewide average,”
and about one-half the hospitals are lower than the statewide average.
Individual hospitals commonly fluctuate above and below the average
from one reporting cycle to the next, which has been true for
Columbia Presbyterian. In the most recent reporting cycle, three
hospitals had risk-adjusted CABG mortality that was “signifi-
cantly” higher than the statewide average, defined as falling outside
the 95% confidence limits. I reiterate, Columbia Presbyterian was
not one of these statistical outliers, and has never been one of
them. Dr. Turi and the editorial board of JACC are certainly
sophisticated enough not to be excused for tossing around the term
“significantly” when not referring to a statistically significant
difference. Never mind the questionable taste employed when
dragging an individual patient into print to score points, just as
Larry Altman did in the New York Times article that Dr. Turi cites
(inaccurately) to support his argument.
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Dr. Smith’s kind categorization of my editorial (1) as generally
both “lucid and well-reasoned” is tempered by what appears to be
lack of awareness of New York State’s report card for his own
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